Skip to content

Integra LifeSciences IART Debt Maturity - 2027

Debt Maturity - 2027 at other companies

ITG
Integer HoldingsITGR
$156M+7.6%
CONMED logo
CONMEDCNMD
$0
ICU Medical logo
ICU MedicalICUI
$582M

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's debt maturity - 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's debt maturity - 2027?
Integra LifeSciences (IART) reported debt maturity - 2027 of $634.53M in Q1 2026.
How has Integra LifeSciences's debt maturity - 2027 changed year-over-year?
Integra LifeSciences's debt maturity - 2027 decreased by 0.0% year-over-year, from $634.53M to $634.53M.
What does debt maturity - 2027 mean?
The specific principal amount of debt obligations scheduled to mature in the year 2027. This metric is essential for assessing the company's liquidity risk and refinancing requirements in a specific future period. It helps investors understand the timing of potential cash outflows related to debt repayment.